THYROCARE Thyrocare Technologies Q4 FY25 results (Jan–Mar 2025) and concall
Thyrocare Technologies reported strong Q4 and full-year FY25 results, driven by robust growth across its Pathology, Franchisee, and Partnership businesses. The company achieved significant margin expansion in Q4 due to better product mix, operating leverage, and reduced doubtful debt provisioning. Strategic initiatives like network expansion, selective acquisitions, and enhanced service offerings, including ECG at home, contributed to its outperformance in the diagnostic industry.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 177 | 166 | 187 |
| EBITDA | 48 | 42 | 57 |
| Net profit | 26 | 19 | 22 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
